Ccnd1 (cyclin D1) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Ccnd1 (cyclin D1) Rattus norvegicus
Analyze
Symbol: Ccnd1
Name: cyclin D1
RGD ID: 68384
Description: Enables protein kinase binding activity. Involved in several processes, including Leydig cell differentiation; response to corticosterone; and response to vitamin E. Predicted to be located in bicellular tight junction and nucleoplasm. Predicted to be part of cyclin D1-CDK4 complex and transcription repressor complex. Predicted to be active in centrosome; cytoplasm; and nucleus. Used to study prostate cancer and status epilepticus. Biomarker of atherosclerosis; impotence; liver cancer; transitional cell carcinoma; and visual epilepsy. Human ortholog(s) of this gene implicated in several diseases, including carcinoma (multiple); colorectal cancer; hematologic cancer (multiple); invasive lobular carcinoma; and von Hippel-Lindau disease. Orthologous to human CCND1 (cyclin D1); PARTICIPATES IN E-cadherin signaling pathway; G1/S transition pathway; Notch signaling pathway; INTERACTS WITH (R)-adrenaline; (R,R,R)-alpha-tocopherol; (S)-colchicine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: G1/S-specific cyclin-D1
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81209,518,288 - 209,527,986 (-)NCBIGRCr8
mRatBN7.21200,089,002 - 200,098,524 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1200,089,002 - 200,098,602 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1208,470,197 - 208,479,709 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01215,556,434 - 215,565,956 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01208,230,641 - 208,240,163 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01218,090,750 - 218,100,447 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1218,090,750 - 218,100,325 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01224,960,136 - 224,969,658 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41205,357,235 - 205,366,757 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11205,510,735 - 205,520,201 (-)NCBI
Celera1197,647,068 - 197,656,590 (-)NCBICelera
Cytogenetic Map1q42NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
adenocarcinoma  (ISO)
adenoid cystic carcinoma  (ISO)
Aicardi-Goutieres Syndrome 3  (ISO)
angiosarcoma  (ISO)
Animal Mammary Neoplasms  (ISO)
atherosclerosis  (IEP)
B-lymphoblastic leukemia/lymphoma  (ISO)
Bowen's Disease  (ISO)
Brain Neoplasms  (ISO)
Breast Neoplasms  (ISO)
bronchiolo-alveolar adenocarcinoma  (ISO)
Burns  (IEP)
carcinoma  (ISO)
Cecal Neoplasms  (ISO)
cervix uteri carcinoma in situ  (ISO)
Chronic Hepatitis C  (ISO)
colon adenoma  (ISO)
Colonic Neoplasms  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
Disease Progression  (ISO)
ductal carcinoma in situ  (ISO)
Endometrial Neoplasms  (ISO)
Esophageal Neoplasms  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Liver Neoplasms  (IEP,ISO)
Experimental Mammary Neoplasms  (IEP,ISO)
Experimental Neoplasms  (ISO)
genetic disease  (ISO)
Genomic Instability  (ISO)
head and neck squamous cell carcinoma  (ISO)
hepatocellular carcinoma  (ISO)
high grade glioma  (ISO)
hyperparathyroidism  (ISO)
Hyperplasia  (ISO)
impotence  (IEP)
intellectual disability  (ISO)
Intestinal Polyps  (ISO)
invasive lobular carcinoma  (ISO)
Kidney Neoplasms  (ISO)
leukemia  (ISO)
liver cancer  (IEP)
Liver Neoplasms  (ISO)
lung adenocarcinoma  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
lung small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
malignant astrocytoma  (ISO)
mantle cell lymphoma  (ISO)
medulloblastoma  (ISO)
multiple myeloma  (ISO)
Myocardial Ischemia  (ISO)
Nasopharyngeal Neoplasms  (ISO)
Neoplasm Metastasis  (ISO)
Neoplastic Cell Transformation  (ISO)
non-Hodgkin lymphoma  (ISO)
ovarian carcinoma  (ISO)
pancreatic adenocarcinoma  (ISO)
pancreatic cancer  (ISO)
pancreatic ductal adenocarcinoma  (ISO)
pancreatic ductal carcinoma  (ISO)
Pancreatic Intraepithelial Neoplasia  (ISO)
pancreatic solid pseudopapillary carcinoma  (ISO)
papilloma  (ISO)
penile benign neoplasm  (ISO)
pre-malignant neoplasm  (ISO)
prostate cancer  (IMP)
prostate carcinoma in situ  (ISO)
Prostatic Neoplasms  (ISO)
Recurrent Infections, with Encephalopathy, Hepatic Dysfunction, and Cardiovascular Malformations  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (IEP)
Salivary Gland Neoplasms  (ISO)
squamous cell carcinoma  (ISO)
status epilepticus  (IDA)
Stomach Neoplasms  (ISO)
thyroid gland papillary carcinoma  (ISO)
Thyroid Neoplasms  (ISO)
tongue squamous cell carcinoma  (ISO)
transitional cell carcinoma  (IEP,ISO)
urinary bladder cancer  (ISO)
Urologic Neoplasms  (ISO)
Uterine Cervical Neoplasms  (ISO)
visual epilepsy  (IEP)
von Hippel-Lindau disease  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (ISO)
(+)-schisandrin B  (ISO)
(+)-Tetrandrine  (ISO)
(-)-Arctigenin  (ISO)
(-)-cotinine  (ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(20R)-protopanaxadiol  (ISO)
(20S)-ginsenoside Rh2  (ISO)
(R)-adrenaline  (EXP,ISO)
(R)-lipoic acid  (ISO)
(R,R,R)-alpha-tocopherol  (EXP)
(S)-colchicine  (EXP,ISO)
(S)-naringenin  (ISO)
(S)-nicotine  (EXP,ISO)
(Z)-3-butylidenephthalide  (EXP,ISO)
(Z)-ligustilide  (ISO)
1'-acetoxychavicol acetate  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP,ISO)
1,2-dimethylhydrazine  (EXP,ISO)
1,3-thiazolidine-2,4-dione  (ISO)
1,4-benzoquinone  (ISO)
1,4-dithiothreitol  (ISO)
1-(4-methoxybenzyl)-3-(5-nitro-1,3-thiazol-2-yl)urea  (ISO)
1-methyltryptophan  (ISO)
1-monopalmitoylglycerol  (ISO)
1-naphthyl isothiocyanate  (EXP,ISO)
1-nitropyrene  (ISO)
14-Deoxy-11,12-didehydroandrographolide  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (EXP,ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
1H-pyrazole  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP,ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3-bis(4-hydroxyphenyl)propionitrile  (ISO)
2,4,6-trinitrotoluene  (EXP)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (EXP)
2,4-Dihydroxybenzophenone  (ISO)
2,4-dinitrotoluene  (EXP)
2,6-di-tert-butyl-4-methylphenol  (ISO)
2,6-dinitrotoluene  (EXP)
2-acetamidofluorene  (EXP)
2-hydroxy-17beta-estradiol  (ISO)
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid  (ISO)
2-hydroxypropanoic acid  (ISO)
2-methoxy-17beta-estradiol  (ISO)
2-methoxyidazoxan  (EXP)
2-nitrofluorene  (EXP)
2-palmitoylglycerol  (ISO)
2-tert-butylhydroquinone  (ISO)
3',5'-cyclic AMP  (EXP,ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,3',5,5'-tetrabromobisphenol A  (EXP)
3,3',5,5'-tetraiodothyroacetic acid  (ISO)
3,3',5-triiodo-L-thyronine  (EXP,ISO)
3,3'-diindolylmethane  (ISO)
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol  (ISO)
3-[(4-anilinophenyl)diazenyl]benzene-1-sulfonic acid  (EXP)
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid  (ISO)
3-aminobenzamide  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (EXP,ISO)
3-methyladenine  (ISO)
3-methylcholanthrene  (ISO)
3-nitropropanoic acid  (EXP)
3-phenylprop-2-enal  (EXP)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (EXP,ISO)
4-hydroxy-17beta-estradiol  (ISO)
4-hydroxy-TEMPO  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-nitrophenol  (ISO)
4-nitroquinoline N-oxide  (ISO)
4-nonylphenol  (EXP,ISO)
4-tert-Octylphenol  (ISO)
5'-S-methyl-5'-thioadenosine  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
5-fluorouracil  (ISO)
5-formyltetrahydrofolic acid  (EXP)
5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole  (EXP)
5-methoxypsoralen  (ISO)
5-Nitro-2-(3-phenylpropylamino)benzoic acid  (ISO)
6-bromoindirubin-3'-oxime  (EXP,ISO)
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide  (EXP)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (EXP,IEP,ISO)
7,9-dihydro-1H-purine-2,6,8(3H)-trione  (ISO)
9,10-anthraquinone  (ISO)
acetaldehyde  (EXP)
acetamide  (EXP)
acetone  (ISO)
acetylleucyl-leucyl-norleucinal  (ISO)
acetylsalicylic acid  (EXP,ISO)
acrylamide  (EXP,ISO)
acrylonitrile  (EXP,ISO)
Actein  (EXP,ISO)
acteoside  (ISO)
actinomycin D  (ISO)
adenosine  (ISO)
Aeroplysinin 1  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (EXP,ISO)
alachlor  (ISO)
aldehydo-D-glucose  (EXP,ISO)
all-trans-acitretin  (ISO)
all-trans-retinoic acid  (EXP,ISO)
all-trans-retinol  (ISO)
allose  (ISO)
alpha-naphthoflavone  (ISO)
alpha-Zearalanol  (ISO)
alternariol  (ISO)
alvocidib  (ISO)
amitrole  (EXP)
amlodipine  (ISO)
ammonium chloride  (EXP)
amodiaquine  (ISO)
amphibole asbestos  (ISO)
andrographolide  (ISO)
androstane  (ISO)
aniline  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
anthracene  (ISO)
antimony(0)  (EXP)
Antrocin  (ISO)
antroquinonol  (ISO)
arecoline  (EXP,ISO)
aristolochic acid A  (ISO)
Aroclor 1254  (ISO)
arotinoid acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
asiatic acid  (EXP)
astragaloside IV  (ISO)
atrazine  (EXP,ISO)
avermectin  (ISO)
azadirachtin A  (ISO)
bacitracin  (EXP)
bafilomycin A1  (ISO)
baicalein  (ISO)
baicalin  (ISO)
benzamides  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzo[b]fluoranthene  (ISO)
Benzo[k]fluoranthene  (ISO)
benzoic acid  (ISO)
benzophenanthridine  (ISO)
Berbamine  (ISO)
berberine  (ISO)
Besigomsin  (ISO)
beta-carotene  (ISO)
beta-hexachlorocyclohexane  (ISO)
beta-ionone  (ISO)
beta-naphthoflavone  (EXP)
betalain  (ISO)
betulinic acid  (ISO)
bexarotene  (EXP,ISO)
bicalutamide  (ISO)
bilirubin IXalpha  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
BMS-754807  (ISO)
boric acid  (ISO)
boron atom  (ISO)
bortezomib  (ISO)
bosutinib  (ISO)
brassinolide  (ISO)
brazilein  (ISO)
brexpiprazole  (ISO)
brilliant green  (ISO)
bromobenzene  (EXP)
bromodichloromethane  (EXP)
bucladesine  (EXP,ISO)
buspirone  (EXP)
Butylbenzyl phthalate  (ISO)
Butylparaben  (ISO)
butyric acid  (EXP)
C.I. Natural Red 20  (EXP,ISO)
cadmium atom  (EXP,ISO)
cadmium dichloride  (EXP,ISO)
caffeine  (ISO)
calcidiol  (ISO)
calciol  (ISO)
calcitriol  (ISO)
calcium atom  (EXP,ISO)
calcium(0)  (EXP,ISO)
calyculin a  (ISO)
camostat  (ISO)
camptothecin  (ISO)
canertinib  (ISO)
cannabidiol  (ISO)
capillarisin  (ISO)
capsaicin  (ISO)
captan  (ISO)
carbamate ester  (ISO)
carbamazepine  (ISO)
carbofuran  (EXP)
carbon nanotube  (ISO)
carbonyl cyanide p-trifluoromethoxyphenylhydrazone  (ISO)
carboplatin  (ISO)
carboxy-PTIO  (ISO)
Cardanol  (ISO)
carmustine  (ISO)
Cassine  (ISO)
celastrol  (ISO)
celecoxib  (EXP,ISO)
ceruletide  (ISO)
chenodeoxycholic acid  (ISO)
CHIR 99021  (ISO)
chlordecone  (ISO)
chlorendic acid  (EXP)
chlorogenic acid  (ISO)
chlorohydrocarbon  (ISO)
chloropicrin  (ISO)
chlorpromazine  (EXP)
chlorpyrifos  (ISO)
cholic acid  (ISO)
choline  (ISO)
chromium(6+)  (EXP,ISO)
chrysene  (ISO)
chrysin 5,7-dimethyl ether  (EXP)
ciglitazone  (EXP,ISO)
Cirsimarin  (ISO)
cisplatin  (EXP,ISO)
clavulone II  (ISO)
clobenpropit  (ISO)
clofarabine  (ISO)
clofibrate  (EXP,ISO)
clofibric acid  (EXP)
clomiphene  (ISO)
clozapine  (EXP)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
cobimetinib  (ISO)
cocaine  (EXP)
coenzyme Q10  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
cordycepin  (EXP,ISO)
corn oil  (EXP)
corticosterone  (EXP)
coumarin  (ISO)
coumarins  (ISO)
coumermycin A1  (ISO)
coumestrol  (ISO)
crocidolite asbestos  (ISO)
crocin-1  (ISO)
crotonaldehyde  (ISO)
cryptolepine  (ISO)
crystal violet  (ISO)
cucurbitacin B  (ISO)
cucurbitacin I  (ISO)
cumene  (ISO)
Cuprizon  (EXP)
curcumin  (EXP,ISO)
cycloastragenol  (ISO)
cycloheximide  (ISO)
Cyclopamine  (ISO)
cyclophosphamide  (ISO)
cyclosporin A  (EXP,ISO)
cyhalothrin  (ISO)
cypermethrin  (ISO)
cyprodinil  (ISO)
D-glucose  (EXP,ISO)
dabrafenib  (ISO)
dactolisib  (ISO)
daidzein  (ISO)
DAPT  (ISO)
DDE  (ISO)
DDT  (ISO)
decabromodiphenyl ether  (EXP)
deguelin  (ISO)
delta-tocotrienol  (ISO)
deoxycholic acid  (EXP)
deoxynivalenol  (ISO)
Deoxyschizandrin  (ISO)
depsipeptide  (ISO)
desferrioxamine B  (ISO)
Destruxin B  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
diazinon  (EXP,ISO)
diazoxide  (ISO)
dibenz[a,h]anthracene  (ISO)
dibenziodolium  (ISO)
dibenzoylmethane  (ISO)
dibutyl phthalate  (ISO)
dichlorine  (EXP)
dichloroacetic acid  (ISO)
diclofenac  (EXP,ISO)
Didymin  (ISO)
dieckol  (ISO)
dieldrin  (EXP)
diethyl maleate  (EXP,ISO)
diethylstilbestrol  (EXP,ISO)
digitonin  (ISO)
digitoxin  (ISO)
dihydro-beta-erythroidine  (ISO)
dimethylarsinic acid  (EXP)
dimethylarsinous acid  (ISO)
Dinitramine  (ISO)
dioscin  (ISO)
diosgenin  (ISO)
dioxygen  (EXP,ISO)
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate  (EXP)
disodium selenite  (EXP,ISO)
disulfiram  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
dronedarone  (ISO)
dutasteride  (ISO)
elemental boron  (ISO)
elemental selenium  (EXP,ISO)
ellipticine  (ISO)
embelin  (ISO)
endosulfan  (EXP,ISO)
entinostat  (ISO)
eriocitrin  (ISO)
eriodictyol  (ISO)
erlotinib hydrochloride  (ISO)
erythrosin B  (ISO)
esculetin  (EXP,ISO)
estragole  (EXP)
etacrynic acid  (ISO)
ethanol  (EXP,ISO)
ethidium  (ISO)
ethosuximide  (EXP)
etoposide  (ISO)
eugenol  (EXP)
everolimus  (ISO)
Evodiamine  (ISO)
farrerol  (ISO)
fenbendazole  (EXP)
fenhexamid  (ISO)
fenofibrate  (EXP,ISO)
ferulic acid  (EXP,ISO)
finasteride  (EXP)
fingolimod hydrochloride  (ISO)
flavanones  (ISO)
flavonoids  (EXP)
fludioxonil  (ISO)
flumequine  (ISO)
fluoranthene  (ISO)
fluoxetine  (EXP,ISO)
folic acid  (ISO)
formaldehyde  (ISO)
formononetin  (EXP,ISO)
fosinopril  (ISO)
fulvestrant  (EXP,ISO)
fumonisin B1  (ISO)
furan  (EXP,ISO)
furazolidone  (ISO)
galangin  (ISO)
gamma-aminobutyric acid  (EXP)
gamma-tocopherol  (ISO)
gefitinib  (ISO)
geldanamycin  (ISO)
gemcitabine  (ISO)
genistein  (ISO)
gentamycin  (EXP)
geraniol  (ISO)
gingerol  (ISO)
glucose  (EXP,ISO)
glutathione  (ISO)
glycitein  (ISO)
glycyrrhizinic acid  (ISO)
glyphosate  (ISO)
gold atom  (ISO)
gold(0)  (ISO)
graphene oxide  (ISO)
guggulsterone  (ISO)
GW 4064  (ISO)
haloperidol  (EXP)
herbicide  (EXP)
hesperetin  (EXP,ISO)
hesperidin  (ISO)
hexachlorobenzene  (ISO)
hexachlorophene  (ISO)
hexadecanoic acid  (EXP)
hexestrol  (ISO)
histamine  (ISO)
hydrazine  (ISO)
hydrogen chloride  (ISO)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
hydroxamic acid  (ISO)
hydroxyurea  (ISO)
hyperforin  (ISO)
Hypsiziprenol-A9  (ISO)
ibuprofen  (ISO)
Indeno[1,2,3-cd]pyrene  (ISO)
indole-3-methanol  (EXP,ISO)
indolin-2-one  (ISO)
indometacin  (EXP,ISO)
inulin  (ISO)
iron atom  (EXP,ISO)
iron(0)  (EXP,ISO)
iron(III) nitrilotriacetate  (EXP)
Isoangustone A  (ISO)
isoflavones  (ISO)
isopimaric acid  (ISO)
isoprenaline  (ISO)
isoprene  (ISO)
isorhamnetin  (ISO)
isosilybin A  (ISO)
isotretinoin  (ISO)
ivermectin  (ISO)
juglone  (ISO)
kaempferol  (EXP,ISO)
kahweol  (ISO)
ketamine  (EXP)
KN-93  (ISO)
kojic acid  (EXP,ISO)
kurarinol  (ISO)
L-1,4-dithiothreitol  (ISO)
L-arginine  (ISO)
L-ascorbic acid  (EXP,ISO)
L-cysteine  (ISO)
L-glutamine  (ISO)
L-methionine  (ISO)
L-mimosine  (ISO)
lactacystin  (ISO)
lamivudine  (ISO)
lapatinib  (ISO)
lead diacetate  (EXP,ISO)
lead(0)  (EXP)
leflunomide  (ISO)
leptomycin B  (ISO)
letrozole  (ISO)
LGK974  (ISO)
Licochalcone A  (ISO)
lidocaine  (ISO)
limonin  (ISO)
linsidomine  (ISO)
lipoic acid  (ISO)
lipopolysaccharide  (ISO)
lithium atom  (EXP)
lithium chloride  (ISO)
lithium hydride  (EXP)
LM-1685  (ISO)
lonafarnib  (ISO)
losartan  (ISO)
lovastatin  (EXP,ISO)
lupeol  (ISO)
lutein  (ISO)
luteolin  (ISO)
LY294002  (EXP,ISO)
lycopene  (EXP,ISO)
Lysocellin  (ISO)
mabuterol  (EXP)
Maduramicin  (ISO)
magnesium atom  (EXP)
Magnolol  (ISO)
malachite green cation  (EXP)
mancozeb  (ISO)
maneb  (EXP,ISO)
manganese atom  (EXP)
manganese(0)  (EXP)
manumycin A  (ISO)
masoprocol  (ISO)
medroxyprogesterone acetate  (ISO)
MeIQx  (ISO)
melatonin  (ISO)
melittin  (ISO)
memantine  (ISO)
menadione  (ISO)
mestranol  (ISO)
metformin  (ISO)
methamphetamine  (EXP)
methapyrilene  (EXP)
methimazole  (EXP)
methotrexate  (EXP,ISO)
methoxychlor  (ISO)
methylarsonic acid  (EXP)
methylisothiazolinone  (ISO)
methylmercury chloride  (EXP,ISO)
methylparaben  (ISO)
methylseleninic acid  (EXP,ISO)
microcystin-LR  (ISO)
mifepristone  (ISO)
MK-2206  (ISO)
ML-7  (EXP,ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monobenzyl phthalate  (ISO)
Monobutylphthalate  (ISO)
monocrotaline  (ISO)
Morroniside  (ISO)
myo-inositol hexakisphosphate  (ISO)
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine  (ISO)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (EXP,ISO)
N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide  (EXP)
N-acetyl-L-cysteine  (EXP,ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (EXP,ISO)
N-butyl-N-(4-hydroxybutyl)nitrosamine  (EXP)
N-ethyl-N-nitrosourea  (EXP)
N-methyl-4-phenylpyridinium  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (EXP,ISO)
N-methyl-N-nitrosourea  (EXP)
N-methylformamide  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
N-nitrosomorpholine  (EXP)
naphthalene  (ISO)
naproxen  (ISO)
naringin  (EXP,ISO)
Neferine  (ISO)
nerolidol  (ISO)
nicardipine  (ISO)
nickel atom  (ISO)
nickel dichloride  (EXP,ISO)
niclosamide  (EXP,ISO)
nicotine  (EXP,ISO)
nimesulide  (EXP,ISO)
nitrogen dioxide  (ISO)
NMN zwitterion  (ISO)
nonivamide  (ISO)
Nonylphenol  (ISO)
NS-398  (ISO)
O-(chloroacetylcarbamoyl)fumagillol  (ISO)
obeticholic acid  (ISO)
ochratoxin A  (ISO)
okadaic acid  (ISO)
oleanolic acid  (EXP,ISO)
oligomycin A  (ISO)
omega-6 fatty acid  (ISO)
omeprazole  (EXP)
omethoate  (ISO)
oridonin  (ISO)
orlistat  (ISO)
orphenadrine  (EXP)
ouabain  (ISO)
oxaliplatin  (EXP,ISO)
ozone  (EXP,ISO)
p-menthan-3-ol  (ISO)
p-tert-Amylphenol  (ISO)
paclitaxel  (ISO)
palbociclib  (ISO)
palmatine  (ISO)
Panduratin A  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
parthenolide  (ISO)
PD 0325901  (ISO)
PD173074  (ISO)
pemetrexed  (ISO)
penconazole  (ISO)
pentachlorophenol  (EXP,ISO)
pentobarbital  (EXP)
perflubutane  (ISO)
perfluorododecanoic acid  (ISO)
perfluoroheptanoic acid  (ISO)
perfluorohexanesulfonic acid  (ISO)
perfluorohexanoic acid  (ISO)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (EXP,ISO)
perindopril  (ISO)
pevonedistat  (ISO)
phenanthrene  (ISO)
phenethyl caffeate  (ISO)
phenethyl isothiocyanate  (ISO)
phenformin  (EXP)
phenobarbital  (EXP,ISO)
phenylbutazone  (ISO)
phenylephrine  (EXP)
phenylhydrazine  (ISO)
phenytoin  (ISO)
PhIP  (EXP,IEP,ISO)
phorbol 13-acetate 12-myristate  (ISO)
phosphatidylcholine  (ISO)
pinosylvin  (ISO)
pioglitazone  (ISO)
piperine  (ISO)
piperonyl butoxide  (EXP,ISO)
pirinixic acid  (EXP,ISO)
piroxicam  (ISO)
platycodin D  (ISO)
plumbagin  (ISO)
pluronic P-123  (EXP)
Poloxamer  (EXP)
potassium chromate  (ISO)
potassium dichromate  (EXP,ISO)
potassium iodide  (EXP)
pregnenolone 16alpha-carbonitrile  (EXP)
probenecid  (ISO)
procymidone  (EXP)
progesterone  (EXP,ISO)
promegestone  (ISO)
propiconazole  (EXP)
propofol  (ISO)
propylparaben  (ISO)
prostaglandin E2  (ISO)
prothioconazole  (ISO)
pterostilbene  (EXP,ISO)
PX-866  (ISO)
pyrene  (ISO)
pyrrolidine dithiocarbamate  (EXP,ISO)
quercetin  (EXP,ISO)
quinacrine  (ISO)
quinolone  (ISO)
rac-1-monopalmitoylglycerol  (ISO)
rac-lactic acid  (ISO)
raloxifene  (EXP,ISO)
reactive oxygen species  (ISO)
regorafenib  (ISO)
reparixin  (ISO)
reserpine  (ISO)
resveratrol  (EXP,ISO)
retinyl acetate  (ISO)
ribavirin  (ISO)
rifampicin  (ISO)
rimonabant  (ISO)
ritonavir  (ISO)
rosmarinic acid  (EXP)
rotenone  (EXP,ISO)
rottlerin  (ISO)
royal jelly  (ISO)
rubitecan  (ISO)
rucaparib  (ISO)
rutin  (ISO)
ruxolitinib  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (EXP)
Salinomycin  (ISO)
SB 203580  (EXP,ISO)
SB 415286  (EXP,ISO)
SB 431542  (EXP,ISO)
Se-methyl-L-selenocysteine  (EXP,ISO)
Se-methylselenocysteine  (EXP,ISO)
selenium atom  (EXP,ISO)
selumetinib  (ISO)
serpentine asbestos  (ISO)
sevoflurane  (EXP)
shikimic acid  (ISO)
Shikonin  (EXP,ISO)
sildenafil citrate  (EXP)
silibinin  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (ISO)
Siomycin A  (ISO)
sirolimus  (EXP,ISO)
SM-164  (ISO)
sodium arsenate  (EXP,ISO)
sodium arsenite  (EXP,ISO)
sodium cholate  (ISO)
sodium dichromate  (EXP)
sodium fluoride  (ISO)
Soman  (EXP)
sorafenib  (EXP,ISO)
soybean oil  (EXP)
spiromesifen  (ISO)
starch  (EXP)
stattic  (EXP,ISO)
sterigmatocystin  (EXP)
streptozocin  (ISO)
sulfadimethoxine  (EXP)
sulfasalazine  (EXP,ISO)
sulforaphane  (ISO)
sulindac  (ISO)
sulindac sulfide  (ISO)
sulindac sulfone  (EXP,ISO)
sunitinib  (ISO)
syringic acid  (ISO)
syringin  (ISO)
T-2 toxin  (EXP,ISO)
tadalafil  (ISO)
taiwanin C  (ISO)
tamibarotene  (ISO)
tamoxifen  (EXP,ISO)
tanespimycin  (ISO)
Tanshinone I  (ISO)
taurocholic acid  (ISO)
tauroursodeoxycholic acid  (EXP)
temozolomide  (ISO)
Temsirolimus  (ISO)
terephthalic acid  (EXP)
tert-butyl ethyl ether  (EXP)
Tesaglitazar  (EXP)
testosterone  (EXP,ISO)
testosterone enanthate  (EXP)
tetracaine  (ISO)
Tetrachlorobisphenol A  (ISO)
tetrachloromethane  (EXP,ISO)
tetracycline  (EXP)
tetraphene  (ISO)
thalidomide  (ISO)
thapsigargin  (ISO)
theaflavin  (ISO)
Theaflavin 3,3'-digallate  (ISO)
theophylline  (EXP,ISO)
thimerosal  (ISO)
thioacetamide  (EXP)
thioridazine  (ISO)
thiostrepton  (ISO)
thymoquinone  (EXP,ISO)
thyroxine  (ISO)
tipifarnib  (ISO)
titanium dioxide  (ISO)
tocopherol  (ISO)
tofacitinib  (ISO)
tolbutamide  (EXP)
Tomentosin  (ISO)
topotecan  (EXP)
trabectedin  (EXP)
trans-piceid  (ISO)
trans-pinosylvin  (ISO)
trichloroethene  (EXP,ISO)
trichostatin A  (ISO)
triclosan  (ISO)
trimethylarsine oxide  (EXP)
Triptolide  (EXP,ISO)
troglitazone  (EXP,ISO)
trovafloxacin  (EXP,ISO)
Tryptanthrine  (ISO)
tunicamycin  (ISO)
Tylophorine  (ISO)
tyrphostin AG 1478  (ISO)
umbelliferone  (ISO)
urea  (ISO)
urethane  (ISO)
ursodeoxycholic acid  (EXP,ISO)
ursolic acid  (ISO)
usnic acid  (ISO)
valproic acid  (ISO)
vemurafenib  (ISO)
vinclozolin  (EXP,ISO)
vinyl carbamate  (ISO)
vismodegib  (ISO)
vitamin E  (EXP,ISO)
vitamin K  (EXP)
vorinostat  (ISO)
warfarin  (EXP)
withaferin A  (ISO)
wogonin  (EXP,ISO)
wortmannin  (EXP,ISO)
xanthohumol  (EXP,ISO)
XAV939  (EXP)
Y-27632  (EXP)
Yangonin  (ISO)
zearalenone  (EXP,ISO)
zebularine  (ISO)
zerumbone  (ISO)
zidovudine  (ISO)
zinc atom  (EXP,ISO)
zinc sulfate  (EXP,ISO)
zinc(0)  (EXP,ISO)
zingerone  (EXP)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
animal organ regeneration  (IEP)
cell division  (IEA)
cell population proliferation  (ISO)
cellular response to organic substance  (ISO)
DNA damage response  (ISO,ISS)
endoplasmic reticulum unfolded protein response  (IEA,ISO)
fat cell differentiation  (IEA,ISO)
G1/S transition of mitotic cell cycle  (IBA,IEA,ISO,ISS,NAS)
lactation  (IEA,ISO)
Leydig cell differentiation  (IMP)
liver development  (IEP)
liver regeneration  (IEA,ISO)
mammary gland alveolus development  (IEA,ISO)
mammary gland epithelial cell proliferation  (IEA,ISO)
mitotic cell cycle phase transition  (IEA)
mitotic G1 DNA damage checkpoint signaling  (IEA,ISO,ISS)
negative regulation of epithelial cell differentiation  (IEA,ISO)
negative regulation of neuron apoptotic process  (IEA,ISO)
negative regulation of transcription by RNA polymerase II  (IEA,ISO,ISS)
neuron differentiation  (IEA,ISO)
positive regulation of cell population proliferation  (IMP)
positive regulation of G1/S transition of mitotic cell cycle  (IBA)
positive regulation of G2/M transition of mitotic cell cycle  (IEA,ISO,ISS)
positive regulation of mammary gland epithelial cell proliferation  (IEA,ISO)
positive regulation of protein phosphorylation  (IEA,ISO,ISS)
re-entry into mitotic cell cycle  (IEA,ISO)
regulation of cell cycle  (ISO)
regulation of G1/S transition of mitotic cell cycle  (ISO)
response to calcium ion  (IEP)
response to corticosterone  (IEP)
response to estradiol  (IEP)
response to estrogen  (IEP)
response to ethanol  (IEP)
response to glucocorticoid  (IEP)
response to iron ion  (IEP)
response to leptin  (IEA,ISO)
response to magnesium ion  (IEP)
response to organic cyclic compound  (IEP)
response to organonitrogen compound  (IDA)
response to steroid hormone  (IEP)
response to UV-A  (IEA,ISO,ISS)
response to vitamin E  (IEP)
response to X-ray  (IEP)
response to xenobiotic stimulus  (IEA,IEP,ISO)
Wnt signaling pathway  (IEA,ISO)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. Bacher U, etal., Exp Hematol. 2013 Dec;41(12):1028-37. doi: 10.1016/j.exphem.2013.09.004. Epub 2013 Sep 20.
2. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. Bachmann K, etal., J Surg Oncol. 2015 Mar;111(3):316-23. doi: 10.1002/jso.23826. Epub 2014 Dec 2.
3. The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. Bahnassy AA, etal., J Egypt Natl Canc Inst. 2006 Dec;18(4):292-302.
4. Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Bartkova J, etal., Gastroenterology. 2001 Jun;120(7):1680-8. doi: 10.1053/gast.2001.24880.
5. Intestinal cell cycle regulations. Interactions of cyclin D1, Cdk4, and p21Cip1. Beauchamp RD, etal., Ann Surg. 1996 May;223(5):620-7; discussion 627-8.
6. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Bergsagel PL, etal., Blood. 2005 Jul 1;106(1):296-303. Epub 2005 Mar 8.
7. Calcium modulates the cyclin D1 expression in a rat parathyroid cell line. Bianchi S, etal., Biochem Biophys Res Commun 1994 Oct 28;204(2):691-700.
8. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Biankin AV, etal., Cancer Res. 2001 Dec 15;61(24):8830-7.
9. D-type cyclins and G1 progression during liver development in the rat. Boylan JM and Gruppuso PA, Biochem Biophys Res Commun. 2005 May 13;330(3):722-30.
10. Chronic iron overload stimulates hepatocyte proliferation and cyclin D1 expression in rodent liver. Brown KE, etal., Transl Res. 2006 Aug;148(2):55-62.
11. Effects of ischemic preconditioning on cyclinD1 expression during early ischemic reperfusion in rats. Cai FG, etal., World J Gastroenterol. 2006 May 14;12(18):2936-40.
12. Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease? Catarino R, etal., Biochem Biophys Res Commun. 2008 May 23;370(1):118-22. Epub 2008 Mar 18.
13. Differential expressions of cyclin D1 associated with better prognosis of cancers of ampulla of Vater. Chang MC, etal., World J Surg. 2007 May;31(5):1135-41. doi: 10.1007/s00268-006-0032-6.
14. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. Chen X, etal., DNA Cell Biol. 2012 Jun;31(6):1107-13. doi: 10.1089/dna.2011.1521. Epub 2012 Feb 3.
15. Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma. Choudhury M and Bansal S, Indian J Pathol Microbiol. 2007 Oct;50(4):708-10.
16. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Christov K, etal., Breast Cancer Res Treat. 2003 Feb;77(3):253-64.
17. Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Ciznadija D, etal., Cancer Res. 2011 Oct 1;71(19):6174-83. doi: 10.1158/0008-5472.CAN-11-1031. Epub 2011 Aug 15.
18. Deregulation of the p16-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway involved in the rat bladder carcinogenesis induced by terephthalic acid-calculi. Cui L, etal., Urol Res. 2006 Oct;34(5):321-8. Epub 2006 Jul 29.
19. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Dai XF and Chen DF, Zhonghua Gan Zang Bing Za Zhi. 2006 Aug;14(8):597-601.
20. Expression of cell cycle proteins in blood vessels of angiotensin II-infused rats: role of AT(1) receptors. Diep QN, etal., Hypertension 2001 Feb;37(2 Part 2):604-8.
21. WNT10A/ß-catenin pathway in tumorigenesis of papillary thyroid carcinoma. Dong T, etal., Oncol Rep. 2017 Aug;38(2):1287-1294. doi: 10.3892/or.2017.5777. Epub 2017 Jul 3.
22. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome. Dragoj M, etal., Tumour Biol. 2015 Nov;36(11):8773-80. doi: 10.1007/s13277-015-3620-y. Epub 2015 Jun 9.
23. Leptin-mediated decrease of cyclin A2 and increase of cyclin D1 expression: relevance for the control of prepubertal rat Leydig cell division and differentiation. Fombonne J, etal., Endocrinology. 2007 May;148(5):2126-37. Epub 2007 Feb 15.
24. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
25. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Gautschi O, etal., Lung Cancer. 2006 Mar;51(3):303-11. Epub 2006 Jan 10.
26. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences Ge JR, etal., Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 Sep;36(5):483-7.
27. Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis. Georgiadou D, etal., APMIS. 2014 Dec;122(12):1230-9. doi: 10.1111/apm.12289. Epub 2014 Jul 22.
28. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
29. The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy. Grabenstatter HL, etal., Neurobiol Dis. 2014 Feb;62:73-85. doi: 10.1016/j.nbd.2013.09.003. Epub 2013 Sep 16.
30. Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. Gupta S, etal., Sci Rep. 2015 Nov 19;5:16811. doi: 10.1038/srep16811.
31. Protein kinase C alpha signaling inhibits cyclin D1 translation in intestinal epithelial cells. Hizli AA, etal., J Biol Chem. 2006 May 26;281(21):14596-603. Epub 2006 Mar 23.
32. Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA. Huang H, etal., Oligonucleotides. 2009 Jun;19(2):151-62. doi: 10.1089/oli.2008.0174.
33. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Huynh H, etal., Mol Cancer Ther. 2007 Nov;6(11):2959-66.
34. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Ito M, etal., Clin Immunol. 2010 Jun;135(3):459-65. doi: 10.1016/j.clim.2010.02.002. Epub 2010 Mar 1.
35. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Janssen JW, etal., Int J Cancer. 2002 Dec 20;102(6):608-14.
36. Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. Jiang W, etal., Cancer Res. 2003 Mar 15;63(6):1228-34.
37. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Jirstrom K, etal., Br J Cancer. 2003 Nov 17;89(10):1920-6.
38. Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells. Joo MK, etal., Int J Oncol. 2015;46(6):2380-8. doi: 10.3892/ijo.2015.2935. Epub 2015 Mar 26.
39. Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor. Jung HG, etal., Life Sci. 2007 Jan 23;80(7):699-708. Epub 2006 Nov 29.
40. Expression of Wnt target genes in solid pseudopapillary tumor of the pancreas: a pilot study. Kang CM, etal., Pancreas. 2009 Mar;38(2):e53-9.
41. Upregulation of rat Ccnd1 gene by exendin-4 in pancreatic beta cell line INS-1: interaction of early growth response-1 with cis-regulatory element. Kang JH, etal., Diabetologia. 2006 May;49(5):969-79. Epub 2006 Mar 18.
42. Expression of G1 cell cycle regulators in rat liver upon repeated exposure to thioacetamide. Kim KT, etal., Korean J Hepatol. 2007 Mar;13(1):81-90.
43. Overexpression of ß-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA-IIA Squamous Cell Lung Cancer Irrespective of Adjuvant Chemotherapy. Kim Y, etal., J Thorac Oncol. 2016 Dec;11(12):2193-2201. doi: 10.1016/j.jtho.2016.07.021. Epub 2016 Aug 4.
44. Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways. Korashy HM, etal., Anticancer Res. 2017 Sep;37(9):4899-4909. doi: 10.21873/anticanres.11899.
45. Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. Latasa MU, etal., PLoS One. 2010 Dec 29;5(12):e15690. doi: 10.1371/journal.pone.0015690.
46. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro. Lee E, etal., BMC Cancer. 2015 Dec 17;15:982. doi: 10.1186/s12885-015-2001-7.
47. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Li R, etal., Hum Pathol. 2008 Dec;39(12):1792-801. doi: 10.1016/j.humpath.2008.05.008. Epub 2008 Aug 19.
48. [Relationship between the expression of beta-cat, cyclin D1 and c-myc and the occurance and biological behavior of pancreatic cancer]. Li YJ and Ji XR, Zhonghua Bing Li Xue Za Zhi. 2003 Jun;32(3):238-41.
49. Radiation-induced molecular changes in rat mammary tissue: possible implications for radiation-induced carcinogenesis. Loree J, etal., Int J Radiat Biol. 2006 Nov;82(11):805-15.
50. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. Luo Y, etal., Hum Pathol. 2013 Jan;44(1):69-76. doi: 10.1016/j.humpath.2012.04.014. Epub 2012 Aug 30.
51. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Maddison LA, etal., Prostate. 2004 Mar 1;58(4):335-44.
52. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Marchetti A, etal., Int J Cancer. 1998 Jan 19;75(2):187-92.
53. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Matthias C, etal., Clin Cancer Res. 1998 Oct;4(10):2411-8.
54. Growth suppression by p16ink4 requires functional retinoblastoma protein. Medema RH, etal., Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93. doi: 10.1073/pnas.92.14.6289.
55. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast. Mercapide J, etal., Mol Carcinog. 2002 Sep;35(1):6-12.
56. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
57. A CRE and the region occupied by a protein induced by growth factors contribute to up-regulation of cyclin D1 expression in hepatocytes. Moriuchi A, etal., Biochem Biophys Res Commun 2003 Jan 10;300(2):415-21.
58. Mouse Genome Database (MGD) Mouse Genome Database (MGD)
59. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Narayanan BA, etal., Clin Cancer Res. 2007 Oct 1;13(19):5965-73.
60. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
61. Amino acids regulate hepatocyte proliferation through modulation of cyclin D1 expression. Nelsen CJ, etal., J Biol Chem 2003 Jul 11;278(28):25853-8.
62. Rate of oxidant stress regulates balance between rat gastric mucosa proliferation and apoptosis. Olguin-Martinez M, etal., Free Radic Biol Med. 2006 Oct 15;41(8):1325-37. Epub 2006 Jul 15.
63. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
64. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. Onay UV, etal., BMC Cancer. 2008 Jan 14;8(1):6.
65. Online Mendelian Inheritance in Man, OMIM (TM). Online Mendelian Inheritance in Man, OMIM (TM).
66. Functional Role of CyclinD1 Polymorphism (G870A) in Modifying Susceptibility and Overall Survival of North Indian Lung Cancer Patients. Pandey A, etal., Tumori. 2017 Dec 1:tj5000707. doi: 10.5301/tj.5000707.
67. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the penis. Papadopoulos O, etal., Anticancer Res. 2007 Jul-Aug;27(4B):2167-74.
68. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced progressive liver carcinogenesis. Parekh P and Rao KV, Cell Biol Int. 2007 Jan;31(1):35-43. Epub 2006 Sep 10.
69. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
70. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
71. Cyclin D1 is up-regulated in hepatocytes in vivo following cell-cycle block induced by retrorsine. Pitzalis S, etal., J Hepatol. 2005 Sep;43(3):485-90.
72. Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation. Pogoriler J, etal., Development. 2006 Oct;133(19):3929-37. doi: 10.1242/dev.02556. Epub 2006 Aug 30.
73. RefSeq and LocusLink: NCBI gene-centered resources Pruitt KD and Maglott DR, Nucleic Acids Res. 2001 Jan 1;29(1):137-40.
74. The CCND1 G870A gene polymorphism and leukemia or non-Hodgkin lymphoma risk: a meta-analysis. Qin LY, etal., Asian Pac J Cancer Prev. 2014;15(16):6923-8.
75. Reactome: A Knowledgebase of Biological Processes Reactome
76. GOA pipeline RGD automated data pipeline
77. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
78. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
79. Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Rickheim DG, etal., Hepatology 2002 Jul;36(1):30-8.
80. Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling. Roy HK, etal., Mol Cancer Ther. 2006 Aug;5(8):2060-9.
81. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. Salama SA, etal., J Soc Gynecol Investig. 2006 Dec;13(8):542-50. Epub 2006 Nov 7.
82. Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis. Sallinen SL, etal., J Pathol. 1999 Jul;188(3):289-93. doi: 10.1002/(SICI)1096-9896(199907)188:3<289::AID-PATH351>3.0.CO;2-X.
83. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Sandhu SK, etal., Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20047-52. doi: 10.1073/pnas.1213764109. Epub 2012 Nov 19.
84. Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population. Satinder K, etal., Mol Cell Biochem. 2008 Jun 12;.
85. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Schwabe RF, etal., Hepatology 2003 Apr;37(4):824-32.
86. cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenzanthracene. Shan L, etal., Carcinogenesis. 2002 Oct;23(10):1561-8.
87. Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. Shan L, etal., Toxicol Pathol. 2005;33(7):768-75.
88. The Pezcoller lecture: cancer cell cycles revisited. Sherr CJ Cancer Res. 2000 Jul 15;60(14):3689-95.
89. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice. Shi SY, etal., J Biol Chem. 2017 Mar 3;292(9):3789-3799. doi: 10.1074/jbc.M116.752519. Epub 2017 Jan 18.
90. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Simile MM, etal., Carcinogenesis. 2004 Mar;25(3):333-41. Epub 2003 Nov 6.
91. Enhanced sequential expression of G1/S cyclins during experimental epatocarcinogenesis and tyrosine phosphorylation. Sundarrajan M, etal., J Environ Pathol Toxicol Oncol. 2001;20(3):189-97.
92. Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1. Sundberg M, etal., J Neurosci. 2006 May 17;26(20):5402-10.
93. Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy. Tamamori-Adachi M, etal., Biochem Biophys Res Commun 2002 Aug 16;296(2):274-80.
94. Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1. Tamura K, etal., Oncogene 1993 Aug;8(8):2113-8.
95. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. Terada Y, etal., J Am Soc Nephrol. 2005 Aug;16(8):2296-305. Epub 2005 Jun 23.
96. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases. Touyz RM and Yao G, J Cell Physiol. 2003 Dec;197(3):326-35.
97. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Wagner M, etal., Genes Dev. 2001 Feb 1;15(3):286-93.
98. Combined effects of FLT3 and NF-kappaB selective inhibitors on acute myeloid leukemia in vivo. Wang C, etal., J Biochem Mol Toxicol. 2012 Jan;26(1):35-43. doi: 10.1002/jbt.20411. Epub 2011 Sep 16.
99. Inhibition of pancreatic cancer cell growth in vivo using a tetracycline-inducible cyclin D1 antisense expression system. Wang JC, etal., Pancreas. 2013 Jan;42(1):141-8. doi: 10.1097/MPA.0b013e3182546de5.
100. [Regulatory mechanisms of PI3K/AKT signaling pathway in acute leukemia]. Wang WL, etal., Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Feb;20(1):18-21.
101. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Wang Y, etal., Cancer Res. 2007 Apr 15;67(8):3698-707.
102. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Weinhold N, etal., Nat Genet. 2013 May;45(5):522-5. doi: 10.1038/ng.2583. Epub 2013 Mar 17.
103. Elevated Orai1 and STIM1 expressions upregulate MACC1 expression to promote tumor cell proliferation, metabolism, migration, and invasion in human gastric cancer. Xia J, etal., Cancer Lett. 2016 Oct 10;381(1):31-40. doi: 10.1016/j.canlet.2016.07.014. Epub 2016 Jul 16.
104. Regulation of Keratinocyte Proliferation in Rats with Deep, Partial-Thickness Scald: Modulation of Cyclin D1-Cyclin-Dependent Kinase 4 and Histone H1 Kinase Activity of M-Phase Promoting Factor. Xie T, etal., J Surg Res. 2007 Sep 20;.
105. Cell Proliferation and Expression of Cell Cycle Regulatory Proteins that Control the G1/S Transition Are Age Dependent and Lobe Specific in the Brown Norway Rat Model of Prostatic Hyperplasia. Yan J and Brown TR, Endocrinology. 2008 Jan;149(1):193-207. Epub 2007 Oct 25.
106. Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression. Yang CC, etal., Urol Int. 2002;69(3):190-4. doi: 10.1159/000063945.
107. Estrogen accelerates G1 to S phase transition and induces a G2/M phase-predominant apoptosis in synthetic vascular smooth muscle cells. Yang Z, etal., Int J Cardiol. 2007 Jun 12;118(3):381-8. Epub 2006 Oct 18.
108. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Yip-Schneider MT, etal., Mol Cancer Ther. 2007 Jun;6(6):1736-44. doi: 10.1158/1535-7163.MCT-06-0794. Epub 2007 May 31.
109. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. Yu J, etal., J Urol. 2004 Dec;172(6 Pt 1):2410-3.
110. Expression and significance of cyclin D1, p27kip1 protein in bronchioloalveolar carcinoma. Yuan JQ, etal., J Zhejiang Univ Sci. 2004 Feb;5(2):235-41.
111. Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population. Zeng Z, etal., Tumour Biol. 2015 Sep;36(9):6891-900. doi: 10.1007/s13277-015-3401-7. Epub 2015 Apr 8.
112. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma. Zhang C, etal., Breast J. 2005 Jan-Feb;11(1):2-8.
113. Effects of chloroquine on GFAP, PCNA and cyclin D1 in hippocampus and cerebral cortex of rats with seizures induced by pentylenetetrazole. Zhang S, etal., J Huazhong Univ Sci Technolog Med Sci. 2005;25(6):625-8.
114. Inhibited activities in CCAAT/enhancer-binding protein, activating protein-1 and cyclins after hepatectomy in rats with thioacetamide-induced liver cirrhosis. Zhao G, etal., Biochem Biophys Res Commun 2002 Mar 29;292(2):474-81.
115. Elevated retinol binding protein 4 levels are associated with atherosclerosis in diabetic rats via JAK2/STAT3 signaling pathway. Zhou W, etal., World J Diabetes. 2021 Apr 15;12(4):466-479. doi: 10.4239/wjd.v12.i4.466.
116. Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Zhu Z, etal., Carcinogenesis. 2003 Jul;24(7):1225-31. Epub 2003 May 9.
Additional References at PubMed
PMID:8114739   PMID:8889548   PMID:8988060   PMID:9190208   PMID:9236224   PMID:10419681   PMID:11747812   PMID:11793365   PMID:11809706   PMID:12048199   PMID:12124778   PMID:12373555  
PMID:12502791   PMID:12588994   PMID:12970760   PMID:15277517   PMID:15314168   PMID:15548426   PMID:15844214   PMID:15958724   PMID:16176978   PMID:16412096   PMID:16489008   PMID:16569215  
PMID:17149750   PMID:17344214   PMID:17420273   PMID:17431217   PMID:17508424   PMID:17556661   PMID:17855062   PMID:18278459   PMID:18291362   PMID:18417529   PMID:18438935   PMID:18483258  
PMID:18604197   PMID:18664382   PMID:18700867   PMID:18929742   PMID:19029821   PMID:19056892   PMID:19060913   PMID:19080278   PMID:19124461   PMID:19412162   PMID:19531352   PMID:19640308  
PMID:19767775   PMID:19847806   PMID:19885954   PMID:19909792   PMID:20037604   PMID:20075866   PMID:20227424   PMID:20235220   PMID:20399237   PMID:20501390   PMID:20924203   PMID:21092636  
PMID:21179739   PMID:21411630   PMID:21465534   PMID:21468580   PMID:21628965   PMID:21693435   PMID:21736902   PMID:21911473   PMID:21928352   PMID:21982980   PMID:22322893   PMID:22354185  
PMID:22374674   PMID:22566696   PMID:22678010   PMID:22833568   PMID:22893700   PMID:23447091   PMID:23466459   PMID:23740243   PMID:23782291   PMID:23869758   PMID:23948595   PMID:24001804  
PMID:24577313   PMID:24914206   PMID:24936138   PMID:25047835   PMID:25093615   PMID:25175461   PMID:25479410   PMID:25535395   PMID:26135564   PMID:26188547   PMID:26657864   PMID:26846850  
PMID:26975029   PMID:27322082   PMID:27333946   PMID:27443256   PMID:27521891   PMID:28983608   PMID:29215736   PMID:29328502   PMID:29351283   PMID:30207314   PMID:30551879   PMID:31034519  
PMID:31549850   PMID:32584130   PMID:32714078   PMID:33314748   PMID:33811247   PMID:34309628   PMID:37684532  


Genomics

Comparative Map Data
Ccnd1
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81209,518,288 - 209,527,986 (-)NCBIGRCr8
mRatBN7.21200,089,002 - 200,098,524 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1200,089,002 - 200,098,602 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1208,470,197 - 208,479,709 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01215,556,434 - 215,565,956 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01208,230,641 - 208,240,163 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01218,090,750 - 218,100,447 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1218,090,750 - 218,100,325 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01224,960,136 - 224,969,658 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41205,357,235 - 205,366,757 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11205,510,735 - 205,520,201 (-)NCBI
Celera1197,647,068 - 197,656,590 (-)NCBICelera
Cytogenetic Map1q42NCBI
CCND1
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381169,641,156 - 69,654,474 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1169,641,156 - 69,654,474 (+)EnsemblGRCh38hg38GRCh38
GRCh371169,455,924 - 69,469,242 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361169,165,054 - 69,178,423 (+)NCBINCBI36Build 36hg18NCBI36
Build 341169,165,053 - 69,178,422NCBI
Celera1166,752,901 - 66,766,272 (+)NCBICelera
Cytogenetic Map11q13.3NCBI
HuRef1165,748,357 - 65,761,725 (+)NCBIHuRef
CHM1_11169,338,874 - 69,352,243 (+)NCBICHM1_1
T2T-CHM13v2.01169,658,031 - 69,671,351 (+)NCBIT2T-CHM13v2.0
Ccnd1
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm397144,483,668 - 144,493,568 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl7144,483,668 - 144,493,662 (-)EnsemblGRCm39 Ensembl
GRCm387144,929,931 - 144,939,831 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl7144,929,931 - 144,939,925 (-)EnsemblGRCm38mm10GRCm38
MGSCv377152,115,836 - 152,125,830 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv367144,739,321 - 144,749,220 (-)NCBIMGSCv36mm8
Celera7144,694,932 - 144,704,928 (-)NCBICelera
Cytogenetic Map7F5NCBI
cM Map788.92NCBI
Ccnd1
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495542216,448,770 - 16,463,300 (-)EnsemblChiLan1.0
ChiLan1.0NW_00495542216,449,921 - 16,462,676 (-)NCBIChiLan1.0ChiLan1.0
CCND1
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v2970,605,973 - 70,620,190 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11171,649,950 - 71,663,325 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01164,737,006 - 64,750,353 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11168,029,134 - 68,041,553 (+)NCBIpanpan1.1PanPan1.1panPan2
CCND1
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11848,501,905 - 48,509,684 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1848,501,899 - 48,516,005 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1847,111,842 - 47,121,415 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01849,179,073 - 49,188,648 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1849,178,951 - 49,189,038 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11848,625,670 - 48,635,233 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01848,211,983 - 48,221,555 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01848,958,012 - 48,967,584 (-)NCBIUU_Cfam_GSD_1.0
Ccnd1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_0244049474,527,409 - 4,541,987 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936599973,838 - 983,316 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
CCND1
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl23,621,246 - 3,633,296 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.123,621,242 - 3,633,380 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.222,342,276 - 2,348,167 (+)NCBISscrofa10.2Sscrofa10.2susScr3
CCND1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.114,909,616 - 4,922,272 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl14,907,353 - 4,922,357 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_023666038102,182,953 - 102,196,194 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Ccnd1
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462476717,469,622 - 17,483,191 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462476717,470,310 - 17,483,082 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Ccnd1
43 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:595
Count of miRNA genes:254
Interacting mature miRNAs:355
Transcripts:ENSRNOT00000028411
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1578780Cm52Cardiac mass QTL 523.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)181591954219808434Rat
731168Bp154Blood pressure QTL 1543.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)194642644214537671Rat
1354591Cm36Cardiac mass QTL 364.1heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1102813953201278233Rat
1354615Cm32Cardiac mass QTL 325.2heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)1102813953201278233Rat
1354606Bp246Blood pressure QTL 2463.6arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)1102813953218753816Rat
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
631549Bp89Blood pressure QTL 895.7arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1123350581201284552Rat
1598853Memor3Memory QTL 34.5exploratory behavior trait (VT:0010471)total horizontal distance resulting from voluntary locomotion in an experimental apparatus (CMO:0001443)1143506580212458660Rat
737828Hcas3Hepatocarcinoma susceptibility QTL 34.9liver integrity trait (VT:0010547)liver tumorous lesion volume to total liver volume ratio (CMO:0001082)1144267353222987745Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
7771612Cm80Cardiac mass QTL 808.4heart left ventricle mass (VT:0007031)heart left ventricle weight (CMO:0000776)1149448574221264292Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354602Bw35Body weight QTL 3512.2body mass (VT:0001259)body weight (CMO:0000012)1151162512201278233Rat
1354620Kidm19Kidney mass QTL 194kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512201278233Rat
1354634Kidm12Kidney mass QTL 123.9kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)1151162512201278233Rat
1354636Lmblg1Limb length QTL 16.4tibia length (VT:0004357)tibia length (CMO:0000450)1151162512201278233Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1358886Bp260Blood pressure QTL 2603.67arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1151162766225824951Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
4889428Stresp24Stress response QTL 240.05heart pumping trait (VT:2000009)absolute change in electrocardiographic low frequency R-R spectral component to high frequency R-R spectral component ratio (CMO:0002162)1155866514200866514Rat
1354618Kidm15Kidney mass QTL 155kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)1156677124201278233Rat
2312420Pur17Proteinuria QTL 177.10.0001urine protein amount (VT:0005160)urine total protein excretion rate (CMO:0000756)1156677124218753816Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
61347Bp197Blood pressure QTL 1974.2arterial blood pressure trait (VT:2000000)blood pressure measurement (CMO:0000003)1158633083203633083Rat
2292222Bp307Blood pressure QTL 3073.060.0014arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393213533942Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
619613Bp77Blood pressure QTL 770.01arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164747424209747424Rat
619613Bp77Blood pressure QTL 770.01arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1164747424209747424Rat
1354653Despr9Despair related QTL 90.00019locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)1167909849212909849Rat
61341Bp26Blood pressure QTL 26arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1169537671214537671Rat
724562Rends1Renal damage susceptibility QTL 10.05kidney glomerulus integrity trait (VT:0010546)index of glomerular damage (CMO:0001135)1169537671214537671Rat
1358294Bw37Body weight QTL 3750.000011body mass (VT:0001259)body weight (CMO:0000012)1171310381216310381Rat
2293689Bss47Bone structure and strength QTL 477.250.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra trabecular cross-sectional area (CMO:0001692)1171629477216629477Rat
2293693Bss22Bone structure and strength QTL 2233.520.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1171629477216629477Rat
2300161Bmd43Bone mineral density QTL 438.40.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1171629477216629477Rat
2300174Bmd42Bone mineral density QTL 428.40.0001lumbar vertebra mineral mass (VT:0010511)bone mineral density (CMO:0001226)1171629477216629477Rat
2300187Bmd41Bone mineral density QTL 418.90.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1171629477216629477Rat
2293654Bss30Bone structure and strength QTL 3032.650.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1171629477216629477Rat
2293673Bss27Bone structure and strength QTL 2718.630.0001femur morphology trait (VT:0000559)femur midshaft cortical cross-sectional area (CMO:0001663)1171629477216629477Rat
2293677Bss41Bone structure and strength QTL 419.380.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1171629477216629477Rat
1549830Bss1Bone structure and strength QTL 14.8femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1172609619217609619Rat
631214Bw61Body weight QTL613.40.0001intramuscular adipose amount (VT:0010044)intramuscular fat area (CMO:0001162)1173108781218108781Rat
70163Bw20Body weight QTL 205.1body mass (VT:0001259)body weight (CMO:0000012)1174133260219133260Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1600380Niddm70Non-insulin dependent diabetes mellitus QTL 703.10.0008blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1176550523221550523Rat
10059600Bp378Blood pressure QTL 3783.080.05arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1176869060221869060Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
1558658Bw59Body weight QTL 593.50.0003body mass (VT:0001259)body weight (CMO:0000012)1178784622223784622Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
1302787Stl25Serum triglyceride level QTL 252.70.0073blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)1180359209210702199Rat
6903303Scl34Serum cholesterol QTL 342.50.0033blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)1180359209218108781Rat
737977Bp160Blood pressure QTL 1600.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1181133855226133855Rat
724559Pancm1Pancreatic morphology QTL 17.1islet of Langerhans morphology trait (VT:0005215)pancreatic islet damage composite score (CMO:0001156)1181759564214537555Rat
2293083Iddm25Insulin dependent diabetes mellitus QTL 254.18blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1181829673224569684Rat
634312Bp143Blood pressure QTL 14330.0002arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1182623426219932796Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
631838Niddm36Non-insulin dependent diabetes mellitus QTL 360.01insulin secretion trait (VT:0003564)calculated pancreatic islet insulin release measurement (CMO:0001217)1184550676229550676Rat
1300145Rf7Renal function QTL 72.96urine creatinine amount (VT:0010540)urine creatinine level (CMO:0000125)1185145134221264292Rat
1359018Hrtrt20Heart rate QTL 203.08heart pumping trait (VT:2000009)heart rate (CMO:0000002)1185356336202902618Rat
2312564Glom18Glomerulus QTL 182.40.003kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1185356336231689108Rat
1582206Kidm33Kidney mass QTL 336.9kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1188377360224054420Rat
6480780Insul18Insulin level QTL 184.11blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1189607473200611765Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
10059590Kidm44Kidney mass QTL 443.420.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1191033875236033875Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
634338Hcar4Hepatocarcinoma resistance QTL 44.6liver integrity trait (VT:0010547)liver tumorous lesion number to liver area ratio (CMO:0001210)1193422268214537671Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1358292Cm37Cardiac mass QTL 376.20.00000081heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat
6480783Insul19Insulin level QTL 194.33blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1197489281200611765Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1197670404242670404Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1197697768238755659Rat
2302375Bw83Body weight QTL 834.870.0002body mass (VT:0001259)body weight (CMO:0000012)1197697768242697768Rat
61376Bp42Blood pressure QTL 4223.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1197814409242814409Rat
1298084Thym4Thymus enlargement QTL 410.68thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)1197814409242814409Rat
1357335Bw39Body weight QTL 393.3body mass (VT:0001259)body weight (CMO:0000012)1197814409242814409Rat
1331790Bp201Blood pressure QTL 2013.127arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1198211513225126682Rat
6480773Gluco64Glucose level QTL 645.09blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459200611765Rat
634313Niddm43Non-insulin dependent diabetes mellitus QTL 43blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459259647894Rat
2292218Kidm35Kidney mass QTL 35kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1199368955224569684Rat
2314011Gluco56Glucose level QTL 56blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1199773958202166723Rat

Markers in Region
D1Wox59  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,091,550 - 200,091,697 (+)MAPPERmRatBN7.2
Rnor_6.01218,093,299 - 218,093,445NCBIRnor6.0
Rnor_5.01224,962,685 - 224,962,831UniSTSRnor5.0
RGSC_v3.41205,359,784 - 205,359,930UniSTSRGSC3.4
Celera1197,649,617 - 197,649,763UniSTS
Cytogenetic Map1q42UniSTS
RH134541  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,089,149 - 200,089,350 (+)MAPPERmRatBN7.2
Rnor_6.01218,090,898 - 218,091,098NCBIRnor6.0
Rnor_5.01224,960,284 - 224,960,484UniSTSRnor5.0
RGSC_v3.41205,357,383 - 205,357,583UniSTSRGSC3.4
Celera1197,647,216 - 197,647,416UniSTS
RH 3.4 Map11561.3UniSTS
Cytogenetic Map1q42UniSTS
BI280117  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,090,348 - 200,090,568 (+)MAPPERmRatBN7.2
Rnor_6.01218,092,097 - 218,092,316NCBIRnor6.0
Rnor_5.01224,961,483 - 224,961,702UniSTSRnor5.0
RGSC_v3.41205,358,582 - 205,358,801UniSTSRGSC3.4
Celera1197,648,415 - 197,648,634UniSTS
RH 3.4 Map11562.61UniSTS
Cytogenetic Map1q42UniSTS
RH133876  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,091,759 - 200,091,939 (+)MAPPERmRatBN7.2
Rnor_6.01218,093,508 - 218,093,687NCBIRnor6.0
Rnor_5.01224,962,894 - 224,963,073UniSTSRnor5.0
RGSC_v3.41205,359,993 - 205,360,172UniSTSRGSC3.4
Celera1197,649,826 - 197,650,005UniSTS
RH 3.4 Map11560.6UniSTS
Cytogenetic Map1q42UniSTS
UniSTS:465472  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,090,353 - 200,090,861 (+)MAPPERmRatBN7.2
Rnor_6.01218,092,102 - 218,092,609NCBIRnor6.0
Rnor_5.01224,961,488 - 224,961,995UniSTSRnor5.0
RGSC_v3.41205,358,587 - 205,359,094UniSTSRGSC3.4
Celera1197,648,420 - 197,648,927UniSTS
Cytogenetic Map1q42UniSTS
PMC321442P2  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,096,019 - 200,096,764 (+)MAPPERmRatBN7.2
Rnor_6.01218,097,768 - 218,098,512NCBIRnor6.0
Rnor_5.01224,967,154 - 224,967,898UniSTSRnor5.0
RGSC_v3.41205,364,253 - 205,364,997UniSTSRGSC3.4
Celera1197,654,086 - 197,654,830UniSTS
Cytogenetic Map1q42UniSTS
PMC98458P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,098,199 - 200,098,399 (+)MAPPERmRatBN7.2
Rnor_6.01218,099,948 - 218,100,147NCBIRnor6.0
Rnor_5.01224,969,334 - 224,969,533UniSTSRnor5.0
RGSC_v3.41205,366,433 - 205,366,632UniSTSRGSC3.4
Celera1197,656,266 - 197,656,465UniSTS
Cytogenetic Map1q42UniSTS
Ccnd1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,091,848 - 200,093,446 (+)MAPPERmRatBN7.2
Rnor_6.01218,093,597 - 218,095,194NCBIRnor6.0
Rnor_5.01224,962,983 - 224,964,580UniSTSRnor5.0
RGSC_v3.41205,360,082 - 205,361,679UniSTSRGSC3.4
Celera1197,649,915 - 197,651,512UniSTS
Cytogenetic Map1q42UniSTS
Ccnd1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21200,096,780 - 200,098,354 (+)MAPPERmRatBN7.2
Rnor_6.01218,098,529 - 218,100,102NCBIRnor6.0
Rnor_5.01224,967,915 - 224,969,488UniSTSRnor5.0
Celera1197,654,847 - 197,656,420UniSTS
Cytogenetic Map1q42UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 43 53 37 19 37 4 5 74 35 34 11 4
Low 4 4 4 4 6 7 4
Below cutoff

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000028411   ⟹   ENSRNOP00000028411
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1200,089,007 - 200,098,602 (-)Ensembl
Rnor_6.0 Ensembl1218,090,750 - 218,100,272 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000088588   ⟹   ENSRNOP00000075372
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1200,089,031 - 200,098,534 (-)Ensembl
Rnor_6.0 Ensembl1218,091,496 - 218,100,325 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000108193   ⟹   ENSRNOP00000083271
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1200,089,002 - 200,098,598 (-)Ensembl
RefSeq Acc Id: NM_171992   ⟹   NP_741989
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81209,518,288 - 209,527,810 (-)NCBI
mRatBN7.21200,089,002 - 200,098,524 (-)NCBI
Rnor_6.01218,090,750 - 218,100,272 (-)NCBI
Rnor_5.01224,960,136 - 224,969,658 (-)NCBI
RGSC_v3.41205,357,235 - 205,366,757 (-)RGD
Celera1197,647,068 - 197,656,590 (-)RGD
Sequence:
RefSeq Acc Id: XM_008760168   ⟹   XP_008758390
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81209,518,288 - 209,527,986 (-)NCBI
mRatBN7.21200,089,002 - 200,098,399 (-)NCBI
Rnor_6.01218,090,750 - 218,100,447 (-)NCBI
Sequence:
Reference Protein Sequences
RefSeq Acc Id: NP_741989   ⟸   NM_171992
- UniProtKB: P39948 (UniProtKB/Swiss-Prot),   A6HYI8 (UniProtKB/TrEMBL),   A6HYI6 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_008758390   ⟸   XM_008760168
- Peptide Label: isoform X1
- UniProtKB: A0A8L2QF92 (UniProtKB/TrEMBL),   A6HYI9 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000028411   ⟸   ENSRNOT00000028411
RefSeq Acc Id: ENSRNOP00000075372   ⟸   ENSRNOT00000088588
RefSeq Acc Id: ENSRNOP00000083271   ⟸   ENSRNOT00000108193
Protein Domains
Cyclin C-terminal   Cyclin N-terminal   Cyclin-like

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P39948-F1-model_v2 AlphaFold P39948 1-295 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13690589
Promoter ID:EPDNEW_R1114
Type:multiple initiation site
Name:Ccnd1_1
Description:cyclin D1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01218,100,285 - 218,100,345EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:68384 AgrOrtholog
BioCyc Gene G2FUF-56836 BioCyc
Ensembl Genes ENSRNOG00000020918 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOG00055020798 UniProtKB/Swiss-Prot
  ENSRNOG00060031868 UniProtKB/Swiss-Prot
  ENSRNOG00065029228 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000028411.4 UniProtKB/TrEMBL
  ENSRNOT00000088588.2 UniProtKB/TrEMBL
  ENSRNOT00000108193 ENTREZGENE
  ENSRNOT00000108193.1 UniProtKB/Swiss-Prot
  ENSRNOT00055035513 UniProtKB/Swiss-Prot
  ENSRNOT00060055245 UniProtKB/Swiss-Prot
  ENSRNOT00065050489 UniProtKB/Swiss-Prot
Gene3D-CATH Cyclin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Cyclin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin-like_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_C-dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclins_cyclin-box UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:58919 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
NCBI Gene 58919 ENTREZGENE
PANTHER PTHR10177 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR10177:SF67 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Cyclin_C UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB CCND1 RGD
PhenoGen Ccnd1 PhenoGen
PROSITE CYCLINS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000020918 RatGTEx
  ENSRNOG00055020798 RatGTEx
  ENSRNOG00060031868 RatGTEx
  ENSRNOG00065029228 RatGTEx
SMART CYCLIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_C UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF47954 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A0G2KAE8_RAT UniProtKB/TrEMBL
  A0A8L2QF92 ENTREZGENE, UniProtKB/TrEMBL
  A6HYI6 ENTREZGENE, UniProtKB/TrEMBL
  A6HYI8 ENTREZGENE, UniProtKB/TrEMBL
  A6HYI9 ENTREZGENE, UniProtKB/TrEMBL
  CCND1_RAT UniProtKB/Swiss-Prot, ENTREZGENE
  Q1JUA4_RAT UniProtKB/TrEMBL


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2002-06-10 Ccnd1  cyclin D1      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_disease expression is lower in the thioacetamide-induced cirrhosis after partial hepatectomy 70813
gene_expression significant in blood vessels of angiotensin 2 infused rats 68887
gene_process required for G1 progression in the cell cycle 68222
gene_process mediates hepatocyte proliferation 727766
gene_regulation induced by several different growth factors including colony stimulating factor-1, epidermal growth factor, and angiotensin 68887
gene_regulation transcription inhibited by by nonessential amino acids (NEAA) deprivation 727766